ArticleRomanian journal of ophthalmology
Transepithelial photorefractive keratectomy for myopia and myopic astigmatism.
Article in Romanian journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Myopia is a growing endemic, especially in the young age groups (E3: 47.2% in 25-29 years old), which is projected to affect up to a staggering 50% of the world's population in the following decades. Transepithelial photorefractive keratomileusis is a novel single-laser refractive surgery that offers advantages in simplicity and corneal biomechanics. Methods: The study reported Trans-PRK results on 71 patients (a total of 137 eyes) with myopia and myopic astigmatism. Results: Mean uncorrected visual acuity at 6 months was 0.02054 logMAR (0.9689 decimal) and at 1 year, 0.02 logMAR (0.9683 decimal); both values were superior to preoperative corrected visual acuity (CDVA). No statistical difference was found between 1 or more months postoperative UCVA and preoperative CDVA (p=0.848-0.723). The efficacy index was over 90% at 1 month and onwards. The safety index was 97% at 1 week and closer to 100% at later follow-up. Cumulative VA 20/20 was achieved in 82.6-89.2% of patients, and 20/25 in 94.2-95.1% of patients. Spherical refraction was +0.13 from plano at 1 month and -0.13 at 6 months; -0.17 at 1 year. Spherical equivalent accuracy was within ±1 D in 87.2% to 95.1% of patients. Vectorial correction index (ideal 1) indicated slight initial overcorrection at 1.19 at 1 month, 1.1 at 6 months, and an almost ideal 1.01 at 1 year; difference vector measured 0.11-0.19D. Discussion: The study reported excellent results using Trans-PRK for the treatment of myopia, as measured by cumulative postoperative uncorrected distance visual acuity, with refractive results aligning with those of comparable studies. Vectorial astigmatism correction was excellent, especially at the 1-year postoperative follow-up, approaching the ideal value. Thus, Trans-PRK offers the expected high-quality correction while presenting biomechanical and simplicity advantages over comparable techniques. Conclusions: Trans-PRK achieved excellent refractive results, a safe profile, and nearly ideal vectorial correction at later follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.